These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 37445623)

  • 1. Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials.
    Popoviciu MS; Păduraru L; Yahya G; Metwally K; Cavalu S
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
    Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
    BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?
    Pedrosa MR; Franco DR; Gieremek HW; Vidal CM; Bronzeri F; de Cassia Rocha A; de Carvalho Cara LG; Fogo SL; Eliaschewitz FG
    Curr Atheroscler Rep; 2022 Nov; 24(11):867-884. PubMed ID: 36044100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials.
    Alkhezi OS; Alahmed AA; Alfayez OM; Alzuman OA; Almutairi AR; Almohammed OA
    Obes Rev; 2023 Mar; 24(3):e13543. PubMed ID: 36579723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
    Camafort-Babkowski M
    Med Clin (Barc); 2013 Aug; 141(4):167-74. PubMed ID: 23332622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging new therapies for the treatment of type 2 diabetes mellitus: glucagon-like peptide-1 receptor agonists.
    Lindamood CA; Taylor JR
    Clin Ther; 2015 Mar; 37(3):483-93. PubMed ID: 25659912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
    Seufert J; Gallwitz B
    Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.
    Sun F; Chai S; Li L; Yu K; Yang Z; Wu S; Zhang Y; Ji L; Zhan S
    J Diabetes Res; 2015; 2015():157201. PubMed ID: 25688373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A new era for glucagon-like peptide-1 receptor agonists].
    Neuville MF; Paquot N; Scheen AJ
    Rev Med Liege; 2023 Jan; 78(1):40-45. PubMed ID: 36634066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
    Guo XH
    Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GLP-1 receptor agonists and cardiovascular outcome trials: An update.
    Andrikou E; Tsioufis C; Andrikou I; Leontsinis I; Tousoulis D; Papanas N
    Hellenic J Cardiol; 2019; 60(6):347-351. PubMed ID: 30528435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
    Gentilella R; Pechtner V; Corcos A; Consoli A
    Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity.
    Jensterle M; Janež A
    Horm Res Paediatr; 2023; 96(6):599-608. PubMed ID: 34852347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials.
    Monami M; Dicembrini I; Nreu B; Andreozzi F; Sesti G; Mannucci E
    Acta Diabetol; 2017 Dec; 54(12):1101-1114. PubMed ID: 28932989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
    Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity.
    Herrou J; Mabilleau G; Lecerf JM; Thomas T; Biver E; Paccou J
    Calcif Tissue Int; 2024 Feb; 114(2):86-97. PubMed ID: 37999750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
    Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
    Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.